Impact of Micrometastatic Axillary Nodes on Survival of Breast Cancer Patients with Tumors ≤2 cm
Hyeon Woo Bae
Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, 03722 Seoul, Republic of Korea
Search for more papers by this authorKwang Hyun Yoon
Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, 03722 Seoul, Republic of Korea
Search for more papers by this authorJoo Heung Kim
Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, 03722 Seoul, Republic of Korea
Search for more papers by this authorSung Mook Lim
Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, 03722 Seoul, Republic of Korea
Search for more papers by this authorJee Ye Kim
Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, 03722 Seoul, Republic of Korea
Search for more papers by this authorHyung Seok Park
Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, 03722 Seoul, Republic of Korea
Search for more papers by this authorCorresponding Author
Seho Park
- [email protected]
- +82-2-2228-2134
Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, 03722 Seoul, Republic of Korea
Frontier Research Institute of Convergence Sports Science, Yonsei University, Seoul, Republic of Korea
Tel.: +82-2-2228-2134, [email protected]Search for more papers by this authorSeung Il Kim
Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, 03722 Seoul, Republic of Korea
Search for more papers by this authorYoung Up Cho
Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, 03722 Seoul, Republic of Korea
Search for more papers by this authorByeong-Woo Park
Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, 03722 Seoul, Republic of Korea
Search for more papers by this authorHyeon Woo Bae
Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, 03722 Seoul, Republic of Korea
Search for more papers by this authorKwang Hyun Yoon
Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, 03722 Seoul, Republic of Korea
Search for more papers by this authorJoo Heung Kim
Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, 03722 Seoul, Republic of Korea
Search for more papers by this authorSung Mook Lim
Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, 03722 Seoul, Republic of Korea
Search for more papers by this authorJee Ye Kim
Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, 03722 Seoul, Republic of Korea
Search for more papers by this authorHyung Seok Park
Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, 03722 Seoul, Republic of Korea
Search for more papers by this authorCorresponding Author
Seho Park
- [email protected]
- +82-2-2228-2134
Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, 03722 Seoul, Republic of Korea
Frontier Research Institute of Convergence Sports Science, Yonsei University, Seoul, Republic of Korea
Tel.: +82-2-2228-2134, [email protected]Search for more papers by this authorSeung Il Kim
Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, 03722 Seoul, Republic of Korea
Search for more papers by this authorYoung Up Cho
Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, 03722 Seoul, Republic of Korea
Search for more papers by this authorByeong-Woo Park
Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, 03722 Seoul, Republic of Korea
Search for more papers by this authorAbstract
Background
This study investigated the impact of pN1mi disease on the survival of T1 breast cancer patients and examined the clinical usefulness of the online PREDICT tool and updated staging system.
Methods
The node stages of 2344 patients were divided into pN0, pN1mi, and pN1a. Clinicopathological parameters and survival outcomes were retrospectively analyzed. Data for 111 micrometastatic diseases were applied to the PREDICT version 2.0 and re-classified using the 8th edition of the cancer staging manual.
Results
Univariable analyses demonstrated worse disease-free and overall survival rates for patients with node-positive cancer; however, the significance was not maintained in multivariable analyses. Chemotherapy improved outcomes in patients with node-positive and non-luminal A-like subtype cancers. The PREDICT tool demonstrated good performance when estimating the 5-year overall survival for pN1mi disease (area under the receiver operating characteristic curve, 0.834). According to the updated staging system, 74% of cases were down-staged to IA, and clearly splitting survival curves were identified.
Conclusion
pN1mi disease alone did not adversely affect survival outcomes. Biologic and treatment factors determined outcomes in cases of small-volume node micrometastasis. The PREDICT tool or new staging classification could help predict the survival of patients with micrometastatic sentinel nodes.
References
- 1BensonJR, della RovereGQ Management of the axilla in women with breast cancer. Lancet Oncol (2007) 8(4): 331–34810.1016/S1470-2045(07)70103-1
- 2GiulianoAE, BallmanKV, McCallL, BeitschPD, BrennanMB, KelemenPR et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (alliance) randomized clinical trial. JAMA (2017) 318(10): 918–92610.1001/jama.2017.11470
- 3ChenSL, HoehneFM, GiulianoAE The prognostic significance of micrometastases in breast cancer: a SEER population-based analysis. Ann Surg Oncol (2007) 14(12): 3378–338410.1245/s10434-007-9513-6
- 4de BoerM, van DijckJA, BultP, BormGF, Tjan-HeijnenVC Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases. J Natl Cancer Inst (2010) 102(6): 410–42510.1093/jnci/djq008
- 5WeaverDL, AshikagaT, KragDN, SkellyJM, AndersonSJ, HarlowSP et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med (2011) 364(5): 412–42110.1056/NEJMoa1008108
- 6HansenNM, GrubeB, YeX, TurnerRR, BrennerRJ, SimMS et al. Impact of micrometastases in the sentinel node of patients with invasive breast cancer. J Clin Oncol (2009) 27(28): 4679–468410.1200/JCO.2008.19.0686
- 7HouvenaeghelG, ClasseJM, GarbayJR, GiardS, CohenM, FaureC et al. Prognostic value of isolated tumor cells and micrometastases of lymph nodes in early-stage breast cancer: a French sentinel node multicenter cohort study. Breast (2014) 23(5): 561–56610.1016/j.breast.2014.04.004
- 8de BoerM, van DeurzenCH, van DijckJA, BormGF, van DiestPJ, AdangEM et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med (2009) 361(7): 653–66310.1056/NEJMoa0904832
- 9GalimbertiV, ColeBF, ZurridaS, VialeG, LuiniA, VeronesiP et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol (2013) 14(4): 297–30510.1016/S1470-2045(13)70035-4
- 10FidlerIJ The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer (2003) 3(6): 453–45810.1038/nrc1098
- 11KleinCA Parallel progression of primary tumours and metastases. Nat Rev Cancer (2009) 9(4): 302–31210.1038/nrc2627
- 12PlichtaJK, CampbellBM, MittendorfEA, HwangES Anatomy and breast cancer staging: is it still relevant?. Surg Oncol Clin N Am (2018) 27(1): 51–6710.1016/j.soc.2017.07.010
- 13RavdinPM, SiminoffLA, DavisGJ, MercerMB, HewlettJ, GersonN et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol (2001) 19(4): 980–99110.1200/JCO.2001.19.4.980
- 14WishartGC, AzzatoEM, GreenbergDC, RashbassJ, KearinsO, LawrenceG et al. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res (2010) 12(1): R110.1186/bcr2464
- 15Candido Dos ReisFJ, WishartGC, DicksEM, GreenbergD, RashbassJ, SchmidtMK et al. An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. Breast Cancer Res (2017) 19(1): 5810.1186/s13058-017-0852-3
- 16EdgeSB, ByrdDR, ComptonCC, FritzAG, GreeneFL, TrottiA AJCC Cancer Staging Manual (2010) 7New YorkSpringer
- 17AminMB, EdgeSB, GreeneFL, ByrdDR, BrooklandRK, WashingtonMK AJCC cancer staging manual (2017) 8New YorkSpringer10.1007/978-3-319-40618-3
10.1007/978-3-319-40618-3 Google Scholar
- 18WeaverDL Pathology evaluation of sentinel lymph nodes in breast cancer: protocol recommendations and rationale. Mod Pathol (2010) 23(Suppl 2): S26–S3210.1038/modpathol.2010.36
- 19HammondME, HayesDF, DowsettM, AllredDC, HagertyKL, BadveS et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 28(16): 2784–279510.1200/JCO.2009.25.6529
- 20WolffAC, HammondME, HicksDG, DowsettM, McShaneLM, AllisonKH et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol (2013) 31(31): 3997–401310.1200/JCO.2013.50.9984
- 21MittendorfEA, BallmanKV, McCallLM, YiM, SahinAA, BedrosianI et al. Evaluation of the stage IB designation of the American Joint Committee on Cancer staging system in breast cancer. J Clin Oncol (2015) 33(10): 1119–112710.1200/JCO.2014.57.2958
- 22IqbalJ, GinsburgO, GiannakeasV, RochonPA, SempleJL, NarodSA The impact of nodal micrometastasis on mortality among women with early-stage breast cancer. Breast Cancer Res Treat (2017) 161(1): 103–11510.1007/s10549-016-4015-5
- 23PepelsMJ, de BoerM, BultP, van DijckJA, van DeurzenCH, Menke-PluymersMB et al. Regional recurrence in breast cancer patients with sentinel node micrometastases and isolated tumor cells. Ann Surg (2012) 255(1): 116–12110.1097/SLA.0b013e31823dc616
- 24HouvenaeghelG, BoherJM, ReyalF, CohenM, GarbayJR, ClasseJM et al. Impact of completion axillary lymph node dissection in patients with breast cancer and isolated tumour cells or micrometastases in sentinel nodes. Eur J Cancer (2016) 67: 106–11810.1016/j.ejca.2016.08.003
- 25LymanGH, TeminS, EdgeSB, NewmanLA, TurnerRR, WeaverDL et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2014) 32(13): 1365–138310.1200/JCO.2013.54.1177
- 26MamtaniA, PatilS, StempelM, MorrowM Axillary micrometastases and isolated tumor cells are not an indication for post-mastectomy radiotherapy in stage 1 and 2 breast cancer. Ann Surg Oncol (2017) 24(8): 2182–218810.1245/s10434-017-5866-7
- 27FrazierTG, FoxKR, SmithJS, LarongaC, McSwainA, PaulD et al. A retrospective study of the impact of 21-gene recurrence score assay on treatment choice in node positive micrometastatic breast cancer. Pharmaceuticals (Basel) (2015) 8(1): 107–12210.3390/ph8010107
- 28HouvenaeghelG, SabatierR, ReyalF, ClasseJM, GiardS, CharitanskyH et al. Axillary lymph node micrometastases decrease triple-negative early breast cancer survival. Br J Cancer (2016) 115(9): 1024–103110.1038/bjc.2016.283
- 29GiulianoAE, ConnollyJL, EdgeSB, MittendorfEA, RugoHS, SolinLJ et al. Breast cancerߝmajor changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin (2017) 67(4): 290–30310.3322/caac.21393
- 30El Hage ChehadeH, WazirU, MokbelK, KasemA, MokbelK Do online prognostication tools represent a valid alternative to genomic profiling in the context of adjuvant treatment of early breast cancer? A systematic review of the literature. Am J Surg (2018) 215(1): 171–17810.1016/j.amjsurg.2017.05.006
- 31JafferS, BleiweissIJ Evolution of sentinel lymph node biopsy in breast cancer, in and out of vogue?. Adv Anat Pathol (2014) 21(6): 433–44210.1097/PAP.0000000000000041
- 32KimbroughCW, McMastersKM, QuilloA, AjkayN Occult metastases in node-negative breast cancer: a surveillance, epidemiology, and end results-based analysis. Surgery (2015) 158(2): 494–50010.1016/j.surg.2015.03.049
